David McKendrick


David McKendrick
David McKendrick is Counsel in Weil’s Private Equity Infrastructure team. He advises infrastructure funds, investors and corporates on M&A and corporate transactions across a broad range of infrastructure assets, including energy, power, renewables, transport, ports, logistics, telecoms, water and waste.

Prior to joining Weil, David worked at A.P. Moller-Maersk in Copenhagen, Denmark. Whilst in his previous role at a UK-headquartered law firm, David completed a client secondment at Vitol.

Representative experience as part of a team, including prior to joining Weil, includes acting for:

  • Global Infrastructure Partners on the $3.9 billion consortium takeover offer for Malaysia Airports Holdings Berhad
  • Global Infrastructure Partners on the sale of a 50.01% stake in Edinburgh Airport to VINCI Airports for £1.27 billion
  • Vitol on its €583 million acquisition of a 35% stake in Saras S.p.A. and subsequent €1.7bn mandatory tender offer
  • InfraBridge on the merger of Freedom Fibre and VX UK, two leading UK altnets
  • APM Terminals on the divestment of Global Ports and its strategic partnership with Hateco in Vietnam
  • ContourGlobal on its acquisition by KKR
  • Green Investment Group on its investment in the Rampion offshore wind farm
  • Maersk on various M&A transactions, including the acquisitions of LF Logistics and Senator International
  • Maersk Growth on its investment in Einride
  • Ørsted on its offshore wind farm projects at Westermost Rough, Race Bank and Hornsea
  • Premier Oil on its merger with Chrysaor to form Harbour Energy
  • Shell on its acquisition of BG
  • Valaris on its Chapter 11 restructuring
  • Värde Partners on the divestment of BizSpace
  • Vitol on its acquisition of the Immingham combined heat and power plant and divestment of GeoAlliance
  • Vodafone on the merger of Vodafone India and Idea Cellular
  • Wood on the divestment of its nuclear business to Jacobs
  • GlaxoSmithKline on the formation of Haleon, its consumer healthcare joint venture with Pfizer